文献速递痛风与晶体性关节病

血清代谢组学揭示高尿酸血症与痛风的代谢通路失调及潜在代谢标志物

Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout.
PubMed 文献 · Arthritis Rheumatol · 2021-08-06

该研究对330例参与者(109例痛风、102例无症状高尿酸血症、119例正常尿酸对照)进行基于高分辨率质谱的血清代谢组学分析,发现痛风与高尿酸血症具有不同的血清代谢组学特征,精氨酸代谢发挥关键作用,并构建了可区分痛风与无症状高尿酸血症的多变量诊断模型。

要点

  • 痛风与无症状高尿酸血症的血清代谢组学特征存在明显差异。
  • 精氨酸代谢在高尿酸血症和痛风的通路失调中可能发挥关键作用。
  • 基于7种代谢物的诊断模型区分痛风与无症状高尿酸血症的AUC在训练集为0.83-0.87,验证集为0.78-0.84。

核心结论

  • 痛风与高尿酸血症具有不同的血清代谢组学特征,所构建的诊断模型有望通过早期检测或预测从高尿酸血症向痛风的进展来改善痛风诊疗。

研究设计与样本

  • 研究纳入330例参与者,包括109例痛风、102例无症状高尿酸血症和119例正常尿酸对照,采用基于高分辨率质谱的代谢组学分析血清样本。
  • 采用多变量主成分分析和正交偏最小二乘判别分析探索差异代谢物与通路,并采用R语言MUVR算法结合随机森林、支持向量机和逻辑回归3种机器学习算法筛选潜在标志物并构建多变量诊断模型。

主要发现

  • 单变量分析显示,痛风患者与正常尿酸对照之间的代谢谱差异大于高尿酸血症个体与正常尿酸对照之间的差异,而痛风与高尿酸血症之间也表现出清晰的代谢组学差异。
  • 通路富集分析发现,与正常尿酸对照相比,高尿酸血症个体和痛风患者存在多种显著失调的通路,其中精氨酸代谢似乎发挥关键作用。
  • 采用MUVR的多变量诊断模型发现13种代谢物可作为区分高尿酸血症和痛风与正常尿酸状态的潜在标志物。
  • 随机选取三分之二样本作为训练集、其余作为验证集,7种代谢物在3种机器学习算法下区分痛风与无症状高尿酸血症的受试者工作特征曲线下面积在训练集为0.83-0.87,在验证集为0.78-0.84。

临床怎么用

  • 血清代谢组学特征及基于7种代谢物的诊断模型有潜力用于区分痛风与无症状高尿酸血症,并可能通过早期检测或预测从高尿酸血症向痛风的进展来改善痛风诊疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically profile metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and to identify potential metabolite biomarkers to discriminate gout from asymptomatic hyperuricemia. METHODS: Serum samples from 330 participants, including 109 with gout, 102 with asymptomatic hyperuricemia, and 119 normouricemic controls, were analyzed by high-resolution mass spectrometry-based metabolomics. Multivariate principal components analysis and orthogonal partial least squares discriminant analysis were performed to explore differential metabolites and pathways. A multivariate methods with Unbiased Variable selection in R (MUVR) algorithm was performed to identify potential biomarkers and build multivariate diagnostic models using 3 machine learning algorithms: random forest, support vector machine, and logistic regression. RESULTS: Univariate analysis demonstrated that there was a greater difference between the metabolic profiles of patients with gout and normouricemic controls than between the metabolic profiles of individuals with hyperuricemia and normouricemic controls, while gout and hyperuricemia showed clear metabolomic differences. Pathway enrichment analysis found diverse significantly dysregulated pathways in individuals with hyperuricemia and patients with gout compared to normouricemic controls, among which arginine metabolism appeared to play a critical role. The multivariate diagnostic model using MUVR found 13 metabolites as potential biomarkers to differentiate hyperuricemia and gout from normouricemia. Two-thirds of the samples were randomly selected as a training set, and the remainder were used as a validation set. Receiver operating characteristic analysis of 7 metabolites yielded an area under the curve of 0.83-0.87 in the training set and 0.78-0.84 in the validation set for distinguishing gout from asymptomatic hyperuricemia by 3 machine learning algorithms. CONCLUSION: Gout and hyperuricemia have distinct serum metabolomic signatures. This diagnostic model has the potential to improve current gout care through early detection or prediction of progression to gout from hyperuricemia.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Shen X, Wang C, Liang N, et al. Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout. Arthritis Rheumatol. 2021. PMID: 33760368. doi:10.1002/art.41733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。